Company: BIVIW
Filing Date: 2025-02-11
Form Type: 10-Q
Source: 0001520138-25-000056
Chunk: 0

Company: BIOVIE INC.
Filing Date: 2025-02-11
Form: 10-Q
Item: Part I, Item 2
Chunk 0
---
This report contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.
Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the
words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,”
“plans,” “expects,” “believes,” “should,” “could,” “may,” “will”
or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements
involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those
expressed or implied by forward-looking statements. These factors include, among others: our research and development activities and distributor
channel; compliance with regulatory requirements; and our ability to satisfy our capital needs Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. 

You are cautioned not to place undue reliance on the
forward-looking statements in this report, which speak only as of the date of this report. Except as may be required by applicable law,
we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking
statements contained in this report as a result of new information or future events or developments, except as required by law. Thus,
you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking
statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the
Securities and Exchange Commission (the “SEC”) that attempt to advise interested parties of the risks, uncertainties and other
factors that may affect our business. 

The following discussion of the Company’s financial
condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere
in this report. 

Management’s Discussion

BioVie Inc. (the “Company” or “we”
or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including
neurological and neuro-degenerative disorders and liver disease. 

Neurodegenerative Disease Program

The Company acquired the biopharmaceutical